[Carbogen therapy in high myopia in children]

Area of Science:

• Ophthalmology
• Pediatric Medicine
• Medical Research

Background:

• High myopia in children presents significant challenges.
• Chorioretinal peripheral dystrophy complicates myopia, impacting visual health.
• Effective treatment strategies for complex pediatric myopia are needed.

Purpose of the Study:

• To evaluate the efficacy of carbogen therapy in children with high myopia.
• To assess the added benefit of carbogen inhalations to standard neurotrophic treatment.
• To investigate the impact on myopia complicated by chorioretinal peripheral dystrophy.

Main Methods:

• A study involving 48 pediatric patients (ages 7-15) with high myopia and chorioretinal dystrophy.
• Patients were divided into a main group (carbogen + neurotrophic treatment) and a control group (neurotrophic treatment only).
• A 10-day treatment course with daily carbogen inhalations was administered to the main group.

Main Results:

• Carbogen therapy was well-tolerated with no reported complications during or after inhalations.
• The main group receiving carbogen therapy showed enhanced treatment efficiency compared to the control group.
• The study demonstrated positive outcomes for high, complicated myopia with carbogen intervention.

Conclusions:

• Carbogen inhalations, as an adjunct to neurotrophic treatment, significantly enhance therapeutic outcomes in pediatric high myopia.
• This combined approach is effective for managing myopia complicated by chorioretinal peripheral dystrophy.
• Carbogen therapy offers a safe and beneficial addition to the treatment of complex pediatric myopia.